Loading
A phase 1 trial of BBI-355 run by Boundless Bio, Inc., terminated.
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications is a phase 1 interventional study registered as NCT05827614 by Boundless Bio, Inc., with 85 participants enrolled, started 2023-03-24. Conditions recorded: Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic and Small Cell Lung Cancer. Interventions recorded: BBI-355, Erlotinib, Futibatinib and BBI-825.
Shares BBI-825, Boundless Bio, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endometrial cancer, Sarcomas (soft tissue, bone, GIST), Head and neck squamous cell carcinoma, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Cervical cancer, Head and neck squamous cell carcinoma, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Cervical cancer, Head and neck squamous cell carcinoma, Ovarian cancer and the tag pipeline.
Shares Small-cell lung cancer, Head and neck squamous cell carcinoma, Ovarian cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Breast cancer (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Small-cell lung cancer, Breast cancer (all types), Triple-negative breast cancer (TNBC), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Boundless Bio, Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/